CP Weesp, Netherlands

Nico Bruins


Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Weesp, NL (2008)
  • CP Weesp, NL (2011)

Company Filing History:


Years Active: 2008-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Inventor Nico Bruins

Introduction

Nico Bruins is a notable inventor based in CP Weesp, Netherlands. He has made significant contributions to the pharmaceutical field, particularly in the development of novel dosage forms and compounds. With a total of 2 patents to his name, Bruins continues to impact the industry through his innovative work.

Latest Patents

One of his latest patents is titled "Bifeprunox mesylate maintenance dose compositions and methods for using the same." This patent provides novel pharmaceutical dosage forms, including a maintenance treatment dose, and outlines methods for making and using these compounds to treat and prevent various diseases and disorders. Another significant patent is for a "Stable crystalline form of bifeprunox mesylate." This invention relates to a stable polymorphic form of the compound 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate, detailing a method for its preparation and its application in pharmaceutical products, especially for treating psychotic disorders and Parkinson's disease.

Career Highlights

Nico Bruins is currently associated with Solvay Pharmaceuticals B.V., where he applies his expertise in pharmaceutical innovations. His work has been instrumental in advancing treatment options for various medical conditions.

Collaborations

Throughout his career, Bruins has collaborated with several professionals in the field, including Irene Eijgendaal and Gerrit Klein. These collaborations have contributed to the successful development of his patented innovations.

Conclusion

Nico Bruins exemplifies the spirit of innovation in the pharmaceutical industry through his patents and collaborative efforts. His work continues to pave the way for advancements in treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…